midazolam has been researched along with Alcoholism in 8 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Alcoholism: A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Abstinent male alcohol dependent subjects underwent [11C]flumazenil PET to measure occupancy of BDZ receptors by midazolam whilst recording its pharmacodynamic effects on behavioural and physiological measures." | 2.71 | GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study. ( Brooks, DJ; Cunningham, VJ; Feeney, A; Lingford-Hughes, AR; Nutt, DJ; Stevenson, B; Wilson, SJ, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dakwar, E | 1 |
| Levin, F | 1 |
| Hart, CL | 1 |
| Basaraba, C | 1 |
| Choi, J | 1 |
| Pavlicova, M | 1 |
| Nunes, EV | 1 |
| Mathew, SJ | 1 |
| Price, RB | 1 |
| Ominami, M | 1 |
| Nagami, Y | 1 |
| Shiba, M | 1 |
| Tominaga, K | 1 |
| Maruyama, H | 1 |
| Okamoto, J | 1 |
| Kato, K | 1 |
| Minamino, H | 1 |
| Fukunaga, S | 1 |
| Sugimori, S | 1 |
| Yamagami, H | 1 |
| Tanigawa, T | 1 |
| Watanabe, T | 1 |
| Fujiwara, Y | 1 |
| Arakawa, T | 1 |
| McCool, BA | 1 |
| Frye, GD | 1 |
| Pulido, MD | 1 |
| Botting, SK | 1 |
| Lingford-Hughes, AR | 1 |
| Wilson, SJ | 1 |
| Cunningham, VJ | 1 |
| Feeney, A | 1 |
| Stevenson, B | 1 |
| Brooks, DJ | 1 |
| Nutt, DJ | 1 |
| Strickland, RA | 1 |
| Berge, KH | 1 |
| Bauer, LO | 1 |
| Gross, JB | 1 |
| Meyer, RE | 1 |
| Greenblatt, DJ | 1 |
| Fiset, L | 1 |
| Milgrom, P | 1 |
| Beirne, OR | 1 |
| Roy-Byrne, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Brief Potent Glutamatergic Modulation on Disordered Alcohol Use[NCT02539511] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence[NCT01904487] | Phase 1 | 11 participants (Actual) | Interventional | 2011-04-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of participants demonstrating alcohol abstinence in the control (midazolam) group versus the active (ketamine) group (NCT02539511)
Timeframe: 21 days post-infusion
| Intervention | percentage of participants (Number) |
|---|---|
| Control Group: Midazolam+MET | 68.6 |
| Active Group: Ketamine+MET | 98.6 |
3 trials available for midazolam and Alcoholism
| Article | Year |
|---|---|
A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial.
Topics: Alcoholism; Combined Modality Therapy; Double-Blind Method; Female; Humans; Infusions, Intravenous; | 2020 |
GABA-benzodiazepine receptor function in alcohol dependence: a combined 11C-flumazenil PET and pharmacodynamic study.
Topics: Adult; Alcoholism; Analysis of Variance; Blood Pressure; Brain; Case-Control Studies; Competitive Bi | 2005 |
Chronic alcohol abuse and the acute sedative and neurophysiologic effects of midazolam.
Topics: Adult; Alcoholism; Anti-Anxiety Agents; Arrhythmia, Sinus; Attention; Dose-Response Relationship, Dr | 1997 |
5 other studies available for midazolam and Alcoholism
| Article | Year |
|---|---|
Ketamine Plus Motivational Enhancement Therapy: Leveraging a Rapid Effect to Promote Enduring Change.
Topics: Alcoholism; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Midazolam; Pilot Projects | 2020 |
Prediction of Poor Response to Modified Neuroleptanalgesia with Midazolam for Endoscopic Submucosal Dissection for Esophageal Squamous Cell Carcinoma.
Topics: Adjuvants, Anesthesia; Aged; Alcoholism; Carcinoma, Squamous Cell; Cross-Sectional Studies; Endoscop | 2016 |
Effects of chronic ethanol consumption on rat GABA(A) and strychnine-sensitive glycine receptors expressed by lateral/basolateral amygdala neurons.
Topics: Alcoholism; Amygdala; Animals; Anti-Anxiety Agents; Anxiety; Benzodiazepines; Central Nervous System | 2003 |
Management of alcohol withdrawal.
Topics: Adrenergic alpha-Agonists; Alcoholism; Anti-Anxiety Agents; Clonidine; Diazepam; Humans; Midazolam; | 1995 |
Disinhibition of behaviors with midazolam: report of a case.
Topics: Adult; Alcoholism; Anesthesia, Dental; Anesthesia, Intravenous; Behavior; Female; Humans; Memory; Mi | 1992 |